<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972539</url>
  </required_header>
  <id_info>
    <org_study_id>20DM10202</org_study_id>
    <nct_id>NCT04972539</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults</brief_title>
  <official_title>A Randomized, Open, Single-dose, 2x2 Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of A51R1 and A51R2 or Administration of AJU-A51 in Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AJU Pharm Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AJU Pharm Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetic characteristics of AJU-A51 in healthy adults&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to assess the safety and pharmacokinetic characteristics between&#xD;
      co-administration of A51R1 with A51R2 and administration of AJU-A51.&#xD;
&#xD;
      This is an open-label, randomized, single-dose, 2x2 crossover study in healthy male and&#xD;
      female subjects to assess the bioequivalence after taking the study drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Actual">March 9, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt(Area Under Curve last) of AJU-A51</measure>
    <time_frame>predose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72hours post-dose</time_frame>
    <description>Area under the plasma concentration time curve of AJU-A51</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72hours post-dose</time_frame>
    <description>The maximum concentration observed of AJU-A51 over blood sampling time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose Period 2: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose Period 2: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AJU-A51 Tab.</intervention_name>
    <description>Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <other_name>Test drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A51R1 Tab. and A51R2 Tab.</intervention_name>
    <description>Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <other_name>Reference drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults over the age of 19 years at the time of screening&#xD;
&#xD;
          2. Individuals who had 18.5 kg/m2 ≤ Body Mass Index(BMI) &lt; 29.9 kg/m2 and total body&#xD;
             weight ≥ 50 kg&#xD;
&#xD;
             * BMI = Weight(kg)/ Height(m)2&#xD;
&#xD;
          3. Individuals who were deemed to be appropriate as study subjects screening&#xD;
             examination(laboratory tests and ECG etc.)&#xD;
&#xD;
          4. Individuals who agreed proper contraception during the study&#xD;
&#xD;
          5. Individuals who signed an informed consent form and decided to participate in the&#xD;
             study after being fully informed of the study prior to participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals with a medical evidence or a history of clinically significant&#xD;
             hepatobiliary, renal, neurologic, respiratory, digestive, endocrine, blood-oncology,&#xD;
             urinary, cardiovascular, musculoskeletal or psychiatric&#xD;
&#xD;
          2. Individuals with an active chronic or acute disease within 1 month.&#xD;
&#xD;
          3. Individuals with a medical history of gastrointestinal disease (e.g., Crohn's disease&#xD;
             and ulcer) or gastrectomy (excluding simple appendectomy or herniotomy) that may&#xD;
             affect drug absorption&#xD;
&#xD;
          4. Individuals with a severe allergies(except for allergic rhinitis or dermatitis)&#xD;
&#xD;
          5. Individuals with the following medical histories at screening test:&#xD;
&#xD;
               -  T1DM or diabetic ketoacidosis&#xD;
&#xD;
               -  Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption&#xD;
                  etc.&#xD;
&#xD;
               -  Renal disorder or pancreatitis etc.&#xD;
&#xD;
          6. A history of regular alcohol consumption exceeding 21 units/week within the 3 months(1&#xD;
             unit = 10 g = 12.5 ml) prior to screening or individuals who cannot quit drinking from&#xD;
             48hr prior to the first&#xD;
&#xD;
          7. Individuals who cannot eat standard meal in institution&#xD;
&#xD;
          8. Women who are pregnant or may be pregnant&#xD;
&#xD;
          9. Individuals who were deemed to be inappropriate to participate in the study by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Hee Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jang Hee Hong</name>
      <address>
        <city>Daejeon</city>
        <state>Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

